UCI study reveals gene linked to breast cancer can suppress tumors

July 28, 2004

Irvine, Calif., July 28, 2004 -- A UC Irvine researcher has found a novel tumor- suppressor function for a gene that, when mutated, often triggers breast cancer in women.

The work also provides further evidence about how estrogen helps activate a disease that afflicts thousands of American women each year.

Dr. Ellis Levin, a professor of medicine, biochemistry and pharmacology at UCI, and colleagues at the Long Beach Veterans Administration Medical Center and Georgetown University Lombardi Cancer Center have identified how the healthy BRCA1 gene prevents the growth and survival of breast cancer cells. The gene accomplishes this by keeping estrogen and growth factor molecules from sending chemical messages through specific signaling pathways on the surface of breast cancer cells - signals that can cause a tumor to grow.

When the BRCA1 gene is mutated, however, it can no longer block this signaling activity from stimulating the growth and survival of cancer cells. The findings suggest that drugs developed to block estrogen signaling at these specific pathways can help curb the incidence of breast cancer in women. The study appears in the July issue of Molecular and Cellular Biology.

Levin said that the findings give further insight into how estrogen can interact with mutant BRCA1 to promote the development of breast cancer. This discovery is important, he added, because women who take estrogen supplements for more than five years to treat menopause symptoms increase their chances of developing breast cancer by about 25 percent.

"The therapeutic goal is to develop estrogen inhibitors that would prevent these types of undesirable effects, yet preserve the positive effects that prevent osteoporosis or hot flashes. Alternatively, enhancing or restoring normal BRCA1 protein function is another approach to consider in women with such BRCA1 mutations," said Levin, who also is chief of endocrinology at UCI and at the VA Medical Center.

It has been long established that mutations in BRCA1 genes strongly increase the risk of breast and ovarian cancer in women and prostate cancer in men; up to 80 percent of women who have this mutated gene ultimately develop breast cancer. Healthy BRCA1 genes are involved with repairing DNA damage, promoting chromosome stability and regulating cell growth activity, but this study has identified a novel and potentially important role as a tumor suppressor. The researchers only studied the tumor-suppressing role of BRCA1 in breast cancer.

Mahnaz Razandi and Ali Pedram of UCI and Dr. Eliot Rosen of Georgetown assisted with the study. The Department of Veterans Affairs, Department of Defense, the National Institutes of Health, the Avon Products Breast Cancer Research Foundation and the Susan B. Komen Breast Cancer Foundation provided support.
-end-
About the University of California, Irvine: The University of California, Irvine is a top-ranked public university dedicated to research, scholarship and community. Founded in 1965, UCI is among the fastest-growing University of California campuses, with approximately 24,000 undergraduate and graduate students and about 1,300 faculty members. The third-largest employer in dynamic Orange County, UCI contributes an annual economic impact of $3 billion.

A complete archive of press releases is available on the World Wide Web at www.today.uci.edu.

University of California - Irvine

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.